AbbVie Testosterone Gel Faces Scrutiny as First Trial Begins
- Company has denied claims gel causes strokes and heart attacks
- Drug’s ‘Low-T’ marketing campaign criticized by patients
Abbott Laboratories' AndroGel
Photographer: Daniel Acker/BloombergThis article is for subscribers only.
Brian DeMatteo said he hoped AbbVie Inc.’s AndroGel would give him more energy when he started taking the testosterone-replacement medicine in 2010. Instead, he claims, the drug put him in a wheelchair.
The 64-year-old Boston businessman blames AndroGel for a spinal stroke that left him a paraplegic suffering from chronic pain in 2012.